admin

Cobwebs Technologies Named ‘Threat Intelligence Platform of the Year’ in 2021 CyberSecurity Breakthrough Awards Program

Prestigious International Awards Program Recognizes Outstanding Information Security Products and Companies CyberSecurity Breakthrough Award – Cobwebs Technologies NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) — Cobwebs Technologies, an industry-leading provider of AI-driven automated digital risk protection platform, today announced that it has been named the winner of the “Threat Intelligence

Read More

First Feature Film NFT Drops from VUELE™ Grossing Nearly Six Figures In Four-Day Auction with Academy Award®-Winner Anthony Hopkins Thriller ZERO CONTACT

New Model Validates Hollywood’s Newest Revenue Stream via Blockchain Distribution BEVERLY HILLS, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — In a groundbreaking venture, global NFT distribution and viewing platform VUELE™ grossed nearly six figures bringing in 32.86267 ETH ($93,435) with the release of eleven total NFT drops of feature film

Read More

Delphix Data Control Tower Achieves SOC 2 Type 1 Compliance

Report Validates Security Protocols of Delphix’s Masking, Compliance, and SaaS Capabilities REDWOOD CITY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — Delphix, the industry leading data company for DevOps, today announced that it has successfully completed a Type 1 System and Organization Controls (SOC) 2 examination for the Delphix Data Control

Read More

AGF Management Limited Reports Third Quarter 2021 Financial Results

TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Reported diluted earnings per share of $0.21 Mutual fund gross sales of $790 million for the third quarter of 2021, an improvement of 61% year-over-year Mutual fund net sales of $288 million for the quarter Total assets under management and fee-earning assets1 of $43.4 billion AGF Management Limited […]

Read More

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma – Health Canada Issues Conditional Approval of TRUSELTIQ under Project Orbis (September 27th, 2021) LUGANO, Switzerland, and PALO ALTO, CA, September 29, 2021 – Helsinn Group and BridgeBio Pharma, Inc.

Read More

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300 mg Intramuscular Dose of ADG20 Given as a Single Intramuscular

Read More